THERAPY DOSSIER · th-bb0d9c43c192

Recombinant adenovirus carrying complementary DNA encoding lysophosphatidylcholine acyltransferase 1 (Ad-LPCAT1)

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25319916 ↗2014Reported benefit

Adenovector-mediated gene transfer of lysophosphatidylcholine acyltransferase 1 attenuates oleic acid-induced acute lung injury in rats.

RatChemical/toxinSprague-DawleyMaleEndobronchial administrationOne week before intravenous oleic acid

Model: Acute lung injury induced by intravenous injection of oleic acid, with lungs examined 4 h later; in vitro hydrogen peroxide exposure of isolated alveolar type II cells

Endobronchial delivery of an LPCAT1 transgene lowered lysophosphatidylcholine content, reduced lung oedema and alveolar type II cell apoptosis, improved lung compliance and attenuated histological oleic acid-induced lung injury compared with Ad-lacZ.

Extraction: extract · Supplied extraction confidence: 0.68. Machine-extracted fields require source verification.

Loading the evidence…